InvestSMART

pSivida Limited (ASX: PSD) - Announcements

DELISTED - Current share price for PSD : $0.093

ASX company news and announcements for pSivida Limited (PSD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All pSivida Limited (PSD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than pSivida Limited (PSD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for pSivida Limited (PSD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Suspension from Official Quotation 11 Jun 2008 2:29PM n/a $0.093 n/a
- pSivida moves to complete reincorporation as a US company 11 Jun 2008 11:34AM n/a $0.093 n/a
- pSivida Receives Court Approval for US Reincorporation 10 Jun 2008 11:37AM $0.093 $0.093 fallen by 0%
- pSivida new trial to treat Age Related Macular Degeneration 9 May 2008 9:49AM $0.096 $0.093 fallen by 3.13%
- Appendix 4C - quarterly 30 Apr 2008 10:04AM $0.105 $0.093 fallen by 11.43%
- pSivida proposed reincorporation in the US - maintain ASX 18 Apr 2008 9:32AM $0.077 $0.093 risen by 20.78%
- pSivida clears Opes Prime overhang 15 Apr 2008 9:26AM $0.077 $0.093 risen by 20.78%
- DSMB again supports continuation of Medidur for DME trial 25 Mar 2008 10:40AM $0.070 $0.093 risen by 32.86%
- Open Briefing. pSivida. Alimera Agreement Amendment 19 Mar 2008 8:29AM $0.073 $0.093 risen by 27.40%
- pSivida generates A$82m from amended licensing amendment 17 Mar 2008 9:37AM $0.079 $0.093 risen by 17.72%
- Trading Halt 14 Mar 2008 1:28PM $0.082 $0.093 risen by 13.41%
- Half Year Accounts 21 Feb 2008 4:22PM $0.075 $0.093 risen by 24%
- pSivida receives first RD payments from Pfizer 20 Feb 2008 9:49AM $0.076 $0.093 risen by 22.37%
- Appendix 4C - quarterly 31 Jan 2008 4:48PM $0.076 $0.093 risen by 22.37%
- Appendix 4C - quarterly 31 Jan 2008 4:48PM $0.076 $0.093 risen by 22.37%
- pSivida pancreatic cancer results released 29 Jan 2008 9:47AM $0.090 $0.093 risen by 3.33%
- pSivida sells pSiNutria business to Intrinsiq (UK) 21 Jan 2008 9:36AM $0.076 $0.093 risen by 22.37%
- Appendix 4C - quarterly 31 Oct 2007 12:40PM $0.110 $0.093 fallen by 15.45%
- DSMB support continuation of Phase III Medidur for DME trial 17 Oct 2007 9:36AM $0.125 $0.093 fallen by 25.60%
- pSivida completes enrollment of Phase III Medidur for DME 8 Oct 2007 9:24AM $0.120 $0.093 fallen by 22.50%
- Preliminary Final Report 31 Aug 2007 12:33PM $0.130 $0.093 fallen by 28.46%
- pSivida enrollment begins on Human PK Study for Medidur 22 Aug 2007 9:34AM $0.115 $0.093 fallen by 19.13%
- PSD completes recruitment of cancer trial/prelim results 13 Aug 2007 8:49AM $0.120 $0.093 fallen by 22.50%
- pSivida Managing Director Open Briefing Interview 2 Aug 2007 9:26AM $0.130 $0.093 fallen by 28.46%
- Appendix 4C - quarterly 31 Jul 2007 4:42PM $0.130 $0.093 fallen by 28.46%

1 - 25 of 141 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.